IV Bisphosphonate q 4 weeks

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Bone Metastases in Men With Hormone-Refractory Prostate Cancer

Conditions

Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma

Trial Timeline

Jan 1, 2005 → Mar 1, 2010

NCT ID

NCT00104650

About IV Bisphosphonate q 4 weeks

IV Bisphosphonate q 4 weeks is a phase 2 stage product being developed by Amgen for Bone Metastases in Men With Hormone-Refractory Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00104650. Target conditions include Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00104650	Phase 2	Completed	Jan 1, 2005	Mar 1, 2010	Bone Metastases in Men With Hormone-Refractory Prostate Cancer

Competing Products

20 competing products in Bone Metastases in Men With Hormone-Refractory Prostate Cancer

See all competitors

Product	Company	Stage	Hype Score
Denosumab + Zoledronic Acid	Daiichi Sankyo	Phase 3	77
Enzalutamide	Astellas Pharma	Phase 2	52
Enzalutamide	Astellas Pharma	Phase 2	52
Tacrolimus	Astellas Pharma	Phase 2	52
Tacrolimus	Astellas Pharma	Phase 2	52
Merestinib	Eli Lilly	Phase 1	33
FORTEO + Placebo	Eli Lilly	Phase 1	33
Arzoxifene + Placebo	Eli Lilly	Phase 3	77
Tanezumab	Eli Lilly	Phase 3	77
Anastrozole + Tamoxifen	AstraZeneca	Phase 3	77
zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements	Novartis	Phase 3	77
Zoledronic acid	Novartis	Phase 3	77
Zoledronic acid + Letrozole	Novartis	Phase 3	77
Zoledronic acid	Novartis	Phase 3	77
Nilotinib	Novartis	Phase 1	33
Reclast (ZOL446, zoledronic acid)	Novartis	Approved	85
Zoledronic acid	Novartis	Phase 3	77
Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid	Novartis	Phase 3	77
zoledronic acid	Novartis	Phase 1	33
Ruxolitinib continuous therapy	Novartis	Phase 2	52

Other Products from Amgen